Clinical Trials › NCT03816345
RecruitingPhase 1
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Sponsored by National Cancer Institute (NCI)
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 300
Target enrollment
19
U.S. states
Jul 2019
Start date
Mar 2028
Expected completion
Interventions / Treatments
Biospecimen CollectionNivolumab
Conditions studied
Multiple Sclerosis
Where this trial is running (51 sites)
Kansas11 sites
Fairway · Hays · Kansas City · +8 more
Missouri9 sites
City of Saint Peters · Creve Coeur · Kansas City · +6 more
Texas5 sites
Dallas · Dallas · Fort Worth · +2 more
New York4 sites
Mineola · New York · New York · +1 more
Maryland3 sites
Baltimore · Bethesda · Bethesda
California2 sites
Palo Alto · Sacramento
Connecticut2 sites
New Haven · New Haven
Illinois2 sites
Chicago · Chicago
Massachusetts2 sites
Boston · Boston
Pennsylvania2 sites
Philadelphia · Pittsburgh
Alabama1 site
Birmingham
District of Columbia1 site
Washington D.C.
Georgia1 site
Atlanta
Kentucky1 site
Lexington
Michigan1 site
Detroit
New Jersey1 site
New Brunswick
Ohio1 site
Columbus
Utah1 site
Salt Lake City
Virginia1 site
Richmond
Participating MS centers on MS Buddy (11)
Emory Multiple Sclerosis Clinic
Atlanta, GA
Atlanta, GA
John L. Trotter Multiple Sclerosis Center
Saint Louis, MO
Saint Louis, MO
Weill Cornell MS Center
New York, NY
New York, NY
Thomas Jefferson University Comprehensive MS Center
Philadelphia, PA
Philadelphia, PA
University of Chicago MS Clinic
Chicago, IL
Chicago, IL
Georgetown Multiple Sclerosis and Neuroimmunology Center
Washington, DC
Washington, DC
Massachusetts General Hospital MS Clinic
Boston, MA
Boston, MA
MS centers in Kansas
Compare treatment centers near a trial site by center type, providers and trials.
View Kansas centers